Download PDF
Thromb Haemost 2006; 95(05): 906-907
DOI: 10.1160/TH06-01-0032
Letters to the Editor
Schattauer GmbH

Increased plasma plasminogen activator inhibitor-1 levels caused by additional aspirin treatment

Toshiyuki Sakata
1   National Cardiovascular Center, Laboratory of Clinical Chemistry, Suita, Osaka, Japan
,
Kazuomi Kario
2   Jichi Medical School, Department of Cardiology, Kawachi, Tochigi, Japan
› Author Affiliations
Further Information

Publication History

Received 18 January 2006

Accepted after resubmission 16 March 2006

Publication Date:
01 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibits and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
    CrossrefPubMedGoogle Scholar
  • 2 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
    CrossrefPubMedGoogle Scholar
  • 3 Sanderson S, Emery J, Baglin T. et al. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142: 370-80.
    CrossrefPubMedGoogle Scholar
  • 4 Cogo A, Ling E, Sturk A. et al. Acetylsalicylic acid inhibits platelet PAI-1 antigen release without affecting circulating PAI-1 antigen in plasma. Ric Clin Lab 1990; 20: 113-7.
    PubMedGoogle Scholar
  • 5 Husted SE, Kristensen SD, Vissinger H. et al. Intravenous acetylsalicylic acid –dose-related effects on platelet function and fibrinolysis in healthy males. Thromb Haemost 1992; 68: 226-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Mousa SA, Forsythe MS, Bozarth JM. et al. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology 1993; 83: 367-73.
    CrossrefPubMedGoogle Scholar
  • 7 Tohgi H, Takahashi H, Chiba K. et al. Coagulationfibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke 1993; 24: 801-4.
    CrossrefPubMedGoogle Scholar
  • 8 Ono T, Sogabe M, Ogura M. et al. Automated latex photometric immunoassay for total plasminogen activator inhibitor-1 in plasma. Clin Chem 2003; 49: 987-9.
    CrossrefPubMedGoogle Scholar
  • 9 Sakata T, Mannami T, Baba S. et al. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Atherosclerosis 2004; 176: 355-60.
    CrossrefPubMedGoogle Scholar
  • 10 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-72.
    CrossrefPubMedGoogle Scholar
  • 11 Declerck PJ, Alessi MC, Verstreken M. et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
    PubMedGoogle Scholar
  • 12 Podor TJ, Singh D, Chindemi P. et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002; 277: 7529-39.
    CrossrefPubMedGoogle Scholar